Literature DB >> 25622983

QT prolongation induced by hydroxyzine: a pharmacovigilance case report.

Jonathan Vigne1, Joachim Alexandre, Fabienne Fobe, Paul Milliez, Magalie Loilier, Sophie Fedrizzi, Antoine Coquerel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25622983     DOI： 10.1007/s00228-014-1804-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.

Authors:  Y G Yap; J Camm
Journal:  BMJ       Date:  2000-04-29

2.  Effects of the histamine H(1) receptor antagonist hydroxyzine on hERG K(+) channels and cardiac action potential duration.

Authors:  Byung Hoon Lee; Seung Ho Lee; Daehyun Chu; Jin Won Hyun; Han Choe; Bok Hee Choi; Su-Hyun Jo
Journal:  Acta Pharmacol Sin       Date:  2011-09       Impact factor: 6.150

3.  Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation.

Authors:  Tomoko Sakaguchi; Hideki Itoh; Wei-Guang Ding; Keiko Tsuji; Iori Nagaoka; Yuko Oka; Takashi Ashihara; Makoto Ito; Yoshihiro Yumoto; Naoko Zenda; Yukei Higashi; Youichi Takeyama; Hiroshi Matsuura; Minoru Horie
Journal:  J Pharmacol Sci       Date:  2008-12-05       Impact factor: 3.337

4.  Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study.

Authors:  Réginald Hulhoven; Dominique Rosillon; Michel Letiexhe; Marie-Anne Meeus; Agnès Daoust; Armel Stockis
Journal:  Eur J Clin Pharmacol       Date:  2007-09-21       Impact factor: 2.953

5.  A simple high-performance liquid chromatographic method for detection of hydroxyzine in human plasma after overdose.

Authors:  Fabienne Péhourcq
Journal:  J Pharmacol Toxicol Methods       Date:  2004 Jul-Aug       Impact factor: 1.950
  5 in total
  5 in total

1.  Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project.

Authors:  Elisabetta Poluzzi; I Diemberger; M De Ridder; A Koci; M Clo; A Oteri; S Pecchioli; I Bezemer; T Schink; S Pilgaard Ulrichsen; G Boriani; M C J Sturkenboom; F De Ponti; G Trifirò
Journal:  Eur J Clin Pharmacol       Date:  2017-08-22       Impact factor: 2.953

Review 2.  Measurement and Management of QT Interval Prolongation for General Physicians.

Authors:  Praveen Indraratna; Daniel Tardo; Madeline Delves; Richard Szirt; Ben Ng
Journal:  J Gen Intern Med       Date:  2019-10-25       Impact factor: 5.128

3.  Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug.

Authors:  Anne-Françoise Schlit; Annie Delaunois; Aurore Colomar; Branderley Claudio; Luca Cariolato; Rossen Boev; Jean-Pierre Valentin; Christopher Peters; Victor S Sloan; Jürgen W G Bentz
Journal:  Pharmacol Res Perspect       Date:  2017-04-21

Review 4.  Towards definitive management of allergic rhinitis: best use of new and established therapies.

Authors:  Lubnaa Hossenbaccus; Sophia Linton; Sarah Garvey; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2020-05-27       Impact factor: 3.406

Review 5.  CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria.

Authors:  Michael N Fein; David A Fischer; Andrew W O'Keefe; Gord L Sussman
Journal:  Allergy Asthma Clin Immunol       Date:  2019-10-01       Impact factor: 3.406
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.